HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (38) Citing Articles via Google Scholar Google Scholar Articles by Stenman, U.-H. Search for Related Content PubMed PubMed Citation Articles by Stenman, U.-H. Related Collections Laboratory Management Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers

New Ultrasensitive Assays Facilitate Studies on the Role of Human Glandular Kallikrein (hK2) as a Marker for Prostatic Disease

Department of Clinical Chemistry, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland, Fax 358-9-4714804, E-mail ulf-hakan.stenman@huch.fi

Prostate cancer is the most common non-skin cancer in men, and it is an important cause of morbidity and mortality. The growth rate of prostate cancer is unusually slow. It has been estimated that the tumor starts developing at 20–30 years of age and reaches a detectable stage 30–40 years later (1). This estimate is based on the doubling time of the serum concentrations of prostate-specific antigen (PSA), ~2 years (2), and the prevalence of high-grade prostatic intraepithelial neoplasia and microscopic cancers in prostates removed at autopsy (3)(4) in various age groups. Studies on archival serum samples from men who later developed prostate cancer have shown that the serum concentrations of PSA begin increasing 5–10 years before clinical presentation(2)(5). When serum PSA exceeds the commonly used cutoff (4 µg/L), the tumor is mostly organ-confined and potentially curable. Therefore, PSA-based screening and case finding is now increasingly used for early detection of this disease (6). However, the value of this screening is debated because the treatment causes morbidity (7) and, although recent data suggest that screening reduces prostate cancer mortality (8), the long-term effect on mortality and quality of life remains to be demonstrated. When prostate cancer is treated without curative intent, the median disease-specific survival is 17 years (5). Thus, it will not be possible to evaluate the long-term effects of screening for another 5–10 years, but it is hardly possible to reverse the trend to screen for prostate cancer until then. However, as laboratorians, we can help to reduce the negative effects of screening by developing better screening tools.

Currently, the main screening tool is serum PSA, which suffers from low specificity . . . [Full Text of this Article]

References

The following articles in journals at HighWire Press have cited this article:

				C. Planque, L. Li, Y. Zheng, A. Soosaipillai, K. Reckamp, D. Chia, E. P. Diamandis, and L. Goodglick A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma Clin. Cancer Res., March 1, 2008; 14(5): 1355 - 1362. [Abstract] [Full Text] [PDF]

				H. Nagahara, K. Mimori, T. Utsunomiya, G. F. Barnard, M. Ohira, K. Hirakawa, and M. Mori Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer Clin. Cancer Res., October 1, 2005; 11(19): 6800 - 6806. [Abstract] [Full Text] [PDF]

				C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]

				B. G. Blijenberg, M. F. Wildhagen, C. H. Bangma, J. A. Finlay, V. Vaisanen, and F. H. Schroder Comparison of Two Assays for Human Kallikrein 2 Clin. Chem., February 1, 2003; 49(2): 243 - 247. [Abstract] [Full Text] [PDF]

				C. D. Petraki, V. N. Karavana, L.-Y. Luo, and E. P. Diamandis Human Kallikrein 10 Expression in Normal Tissues by Immunohistochemistry J. Histochem. Cytochem., September 1, 2002; 50(9): 1247 - 1261. [Abstract] [Full Text] [PDF]

				G. M. Yousef, A. Scorilas, L. G. Kyriakopoulou, L. Rendl, M. Diamandis, R. Ponzone, N. Biglia, M. Giai, R. Roagna, P. Sismondi, et al. Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer Clin. Chem., August 1, 2002; 48(8): 1241 - 1250. [Abstract] [Full Text] [PDF]

				C. D. Petraki, V. N. Karavana, P. T. Skoufogiannis, S. P. Little, D. J.C. Howarth, G. M. Yousef, and E. P. Diamandis The Spectrum of Human Kallikrein 6 (Zyme/Protease M/Neurosin) Expression in Human Tissues as Assessed by Immunohistochemistry J. Histochem. Cytochem., November 1, 2001; 49(11): 1431 - 1442. [Abstract] [Full Text] [PDF]

				G. M. Yousef, L. G. Kyriakopoulou, A. Scorilas, S. Fracchioli, B. Ghiringhello, M. Zarghooni, A. Chang, M. Diamandis, G. Giardina, W. J. Hartwick, et al. Quantitative Expression of the Human Kallikrein Gene 9 (KLK9) in Ovarian Cancer: A New Independent and Favorable Prognostic Marker Cancer Res., November 1, 2001; 61(21): 7811 - 7818. [Abstract] [Full Text] [PDF]

				G. M. Yousef and E. P. Diamandis The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease Endocr. Rev., April 1, 2001; 22(2): 184 - 204. [Abstract] [Full Text]

				G. M. Yousef, A. Magklara, A. Chang, K. Jung, D. Katsaros, and E. P. Diamandis Cloning of a New Member of the Human Kallikrein Gene Family, KLK14, Which Is Down-Regulated in Different Malignancies Cancer Res., April 1, 2001; 61(8): 3425 - 3431. [Abstract] [Full Text]

				C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147. [Abstract] [Full Text]

				E. P. Diamandis Prostate-specific Antigen: A Cancer Fighter and a Valuable Messenger? Clin. Chem., July 1, 2000; 46(7): 896 - 900. [Abstract] [Full Text] [PDF]

				G. M. Yousef, A. Chang, and E. P. Diamandis Identification and Characterization of KLK-L4, a New Kallikrein-like Gene That Appears to be Down-regulated in Breast Cancer Tissues J. Biol. Chem., April 14, 2000; 275(16): 11891 - 11898. [Abstract] [Full Text] [PDF]

				G. M. Yousef and E. P. Diamandis The New Kallikrein-like Gene, KLK-L2. MOLECULAR CHARACTERIZATION, MAPPING, TISSUE EXPRESSION, AND HORMONAL REGULATION J. Biol. Chem., December 31, 1999; 274(53): 37511 - 37516. [Abstract] [Full Text] [PDF]

				A. Magklara, A. Scorilas, W. J. Catalona, and E. P. Diamandis The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA Clin. Chem., November 1, 1999; 45(11): 1960 - 1966. [Abstract] [Full Text] [PDF]

				G. M. Yousef, A. Scorilas, K. Jung, L. K. Ashworth, and E. P. Diamandis Molecular Cloning of the Human Kallikrein 15 Gene (KLK15). UP-REGULATION IN PROSTATE CANCER J. Biol. Chem., January 5, 2001; 276(1): 53 - 61. [Abstract] [Full Text] [PDF]

				L.-M. Chen, M. L. Skinner, S. W. Kauffman, J. Chao, L. Chao, C. D. Thaler, and K. X. Chai Prostasin Is a Glycosylphosphatidylinositol-anchored Active Serine Protease J. Biol. Chem., June 8, 2001; 276(24): 21434 - 21442. [Abstract] [Full Text] [PDF]